Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia
Primary Objective:

To evaluate safety of rasburicase in pediatric patients with NHL and AL

Secondary Objective:

To assess efficacy of rasburicase for prevention and treatment of hyperuricemia
Lymphoma
DRUG: RASBURICASE SR29142
Incidence of AEs and SAEs, Incidence of AE or SAE will be summarized as the number and percentage of subjects who experienced any AE or SAE during the treatment period., Day 1 to Day 7
Number of responders after completion of rasburicase treatment under chemotherapy, Response will be defined as achievement of normal uric acid levels (≤ 8.0 mg/dL) in those patients whose uric acid levels are \>8.0 mg/dL., Day 1 to Day 7|Proportion of patients who can maintain the normal uric acid levels throughout the study, In those patients whose baseline plasma uric acid levels are ≤ 8 mg/dL but with a high risk of TLS., Day 1 to Day 7|Percentage of the maximum decreasing degree of plasma uric acid level from baseline, Day 1 to Day 7
Study duration per participants is approximatively 14 days including a 5-day treatment period.